Integra Lifesciences Holdings (IART) Total Liabilities (2009 - 2026)

Integra Lifesciences Holdings has disclosed Total Liabilities across 18 years of filings, most recently posting $2.5 billion for Q2 2026.

• In Q2 2026, Total Liabilities fell 4.15% year-over-year to $2.5 billion; the TTM figure through Jun 2026 stood at $2.5 billion (down 4.15% YoY), while the FY2025 annual figure was $2.6 billion, up 2.66% from the prior year.
• Total Liabilities came in at $2.5 billion for Q2 2026 at Integra Lifesciences Holdings, down from $2.5 billion in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $2.6 billion in Q2 2025 to a low of $2.1 billion in Q1 2022.
• Average Total Liabilities over 5 years is $2.3 billion, with a median of $2.5 billion recorded in 2024.
• Year-over-year, Total Liabilities fell 7.03% in 2022 and rose 21.29% in 2024.
• Over 5 years, Total Liabilities stood at $2.1 billion in 2022, then advanced by 5.21% to $2.2 billion in 2023, then advanced by 13.58% to $2.5 billion in 2024, then increased by 2.66% to $2.6 billion in 2025, then retreated by 1.5% to $2.5 billion in 2026.
• Per Business Quant data, the three most recent Total Liabilities figures were $2.5 billion in Q2 2026, $2.5 billion in Q1 2026, and $2.6 billion in Q4 2025.